These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 23755891)

  • 81. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.
    Lips EH; Michaut M; Hoogstraat M; Mulder L; Besselink NJ; Koudijs MJ; Cuppen E; Voest EE; Bernards R; Nederlof PM; Wesseling J; Rodenhuis S; Wessels LF;
    Breast Cancer Res; 2015 Oct; 17(1):134. PubMed ID: 26433948
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
    Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
    Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer.
    Johnson JP; Kumar P; Koulnis M; Patel M; Simin K
    Cancer Genomics Proteomics; 2014; 11(3):115-26. PubMed ID: 24969692
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer.
    Dimas-González J; Maldonado-Lagunas V; Díaz-Chávez J; López-Arellano ME; Muñoz-Camacho J; Terán-Porcayo MA; Lagunas-Martínez A
    Oncol Rep; 2017 May; 37(5):3026-3036. PubMed ID: 28393224
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 86. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.
    Park HS; Jang MH; Kim EJ; Kim HJ; Lee HJ; Kim YJ; Kim JH; Kang E; Kim SW; Kim IA; Park SY
    Mod Pathol; 2014 Sep; 27(9):1212-22. PubMed ID: 24406864
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.
    Ogden A; Bhattarai S; Sahoo B; Mongan NP; Alsaleem M; Green AR; Aleskandarany M; Ellis IO; Pattni S; Li XB; Moreno CS; Krishnamurti U; Janssen EA; Jonsdottir K; Rakha E; Rida P; Aneja R
    Sci Rep; 2020 Feb; 10(1):3009. PubMed ID: 32080212
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
    Zhao J; Zhao D; Poage GM; Mazumdar A; Zhang Y; Hill JL; Hartman ZC; Savage MI; Mills GB; Brown PH
    J Clin Invest; 2015 Jul; 125(7):2707-20. PubMed ID: 26075823
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
    Savage P; Blanchet-Cohen A; Revil T; Badescu D; Saleh SMI; Wang YC; Zuo D; Liu L; Bertos NR; Munoz-Ramos V; Basik M; Petrecca K; Asselah J; Meterissian S; Guiot MC; Omeroglu A; Kleinman CL; Park M; Ragoussis J
    Cell Rep; 2017 Oct; 21(5):1140-1149. PubMed ID: 29091754
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
    Lee A; Djamgoz MBA
    Cancer Treat Rev; 2018 Jan; 62():110-122. PubMed ID: 29202431
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.
    Camorani S; Crescenzi E; Gramanzini M; Fedele M; Zannetti A; Cerchia L
    Sci Rep; 2017 Apr; 7():46659. PubMed ID: 28425453
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
    Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
    Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.
    Liu H; Paddock MN; Wang H; Murphy CJ; Geck RC; Navarro AJ; Wulf GM; Elemento O; Haucke V; Cantley LC; Toker A
    Cancer Discov; 2020 Aug; 10(8):1226-1239. PubMed ID: 32513774
    [TBL] [Abstract][Full Text] [Related]  

  • 94. ΔNp63α expression induces loss of cell adhesion in triple-negative breast cancer cells.
    Nekulova M; Holcakova J; Gu X; Hrabal V; Galtsidis S; Orzol P; Liu Y; Logotheti S; Zoumpourlis V; Nylander K; Coates PJ; Vojtesek B
    BMC Cancer; 2016 Oct; 16(1):782. PubMed ID: 27724925
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
    Morrison CD; Chang JC; Keri RA; Schiemann WP
    Cell Death Dis; 2017 Jun; 8(6):e2899. PubMed ID: 28661474
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis.
    Zhang L; Fang C; Xu X; Li A; Cai Q; Long X
    Biomed Res Int; 2015; 2015():357485. PubMed ID: 25695063
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy.
    Su YC; Burnouf PA; Chuang KH; Chen BM; Cheng TL; Roffler SR
    Nat Commun; 2017 Jun; 8():15507. PubMed ID: 28593948
    [TBL] [Abstract][Full Text] [Related]  

  • 98. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Cao W; Li J; Hao Q; Vadgama JV; Wu Y
    Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936
    [TBL] [Abstract][Full Text] [Related]  

  • 99. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.
    Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM
    Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.
    Shen M; Jiang YZ; Wei Y; Ell B; Sheng X; Esposito M; Kang J; Hang X; Zheng H; Rowicki M; Zhang L; Shih WJ; Celià-Terrassa T; Liu Y; Cristea I; Shao ZM; Kang Y
    Cancer Cell; 2019 Jan; 35(1):64-80.e7. PubMed ID: 30612941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.